DEFA14A ·Filed Apr 22, 2026

XENE

Xenon Pharmaceuticals Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001193125-26-170335
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for any shareholder dissent on executive compensation, though this routine filing suggests business as usual.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
XENE ▲ +19.18% at T+60d
NEUTRAL call ✓ call won +19.18% · α vs SPY +14.17% · entry $55.41 → $66.04
Entry anchored
Apr 22, 03:59 PM ET
via exchange tick
T+1d
-0.31%
call -0.31% · α -1.09%
$55.24
settled 5mo ago
T+5d
+0.61%
call +0.61% · α -0.86%
$55.75
settled 5mo ago
T+20d
-1.32%
call -1.32% · α -5.95%
$54.68
settled 5mo ago
T+60d
+19.18%
call +19.18% · α +14.17%
$66.04
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Xenon Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting, proposing the re-election of eight directors, approval of executive compensation, and reappointment of its auditor. This routine filing follows a recent amendment to its equity incentive plan, indicating ongoing governance activities.

Key Facts

  • Filing is a definitive proxy statement (DEFA14A) for the 2025 annual meeting
  • Proposes re-election of eight directors including Dawn Svoronos, Gillian Cannon, and Justin Gover
  • Seeks approval of executive compensation and reappointment of PwC as auditor
  • Follows recent 8-K filing amending the equity incentive plan

Financial Impact

Routine governance filing with no immediate financial impact

governanceexecutive compensation

Risk Factors

  • Potential shareholder dissent on executive compensation
  • Board continuity risk if any directors are not re-elected

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-170335
Document: 0001193125-26-170335-index-headers.html0001193125-26-170335
Document: 0001193125-26-170335-index.html0001193125-26-170335
Document: 0001193125-26-170335.txt0001193125-26-170335
11 reports for XENE
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+60▲ +18.60%Apr 19, 2026
Filters
Rows
Reports for XENE — sortable, filterable
TypeNow
Jul 2, 2026
13w ago
Press Release
NEUTRAL ★ 1/10
$60.96 $64.19▲ +5.30%▲ +5.71%$38.02 (−37.63%)
Jun 5, 2026
16w ago
144
NEUTRAL ★ 2/10
$51.21 $60.54▲ +18.22%▲ +16.59%$38.02 (−25.76%)
Jun 3, 2026
17w ago
8-K
NEUTRAL ★ 3/10
$52.99 $60.96▲ +15.04%▲ +16.41%$38.02 (−28.25%)
May 7, 2026
21w ago
Press Release
MIXED ★ 6/10
$56.44 $51.73▼ −8.35%▼ −8.37%$38.02 (−32.64%)
Apr 22, 2026
23w ago
DEFA14A
NEUTRAL ★ 2/10
$55.41 $54.68▼ −1.32%▼ −5.95%$38.02 (−31.38%)
Apr 19, 2026
23w ago
Press Release
BULLISH ★ 8/10
$57.09 $53.71▼ −5.92%▼ −10.12%$38.02 (−33.40%)
Apr 15, 2026
24w ago
Press Release
BEARISH ★ 5/10
$58.88 $55.00▲ +6.59%▲ +12.63%$38.02 (+35.43%)
Apr 13, 2026
24w ago
8-K
NEUTRAL ★ 3/10
$59.35 $55.78▼ −6.02%▼ −12.31%$38.02 (−35.94%)
Apr 7, 2026
25w ago
Press Release
BEARISH ★ 5/10
$57.65 $57.40▲ +0.43%▲ +10.21%$38.02 (+34.05%)
Mar 13, 2026
29w ago
Insider Cluster
BEARISH ★ 6/10
$55.23 $58.60▼ −6.10%▼ −2.51%$38.02 (+31.16%)
Showing 10 of 11

US Market Status

Market Closed — Opens Mon (64h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access